Protein degraders, a novel approach in drug discovery, show promise to tackle diseases previously thought to be untreatable.

Unlike traditional drugs that block specific protein functions, degraders alter the cell's natural degradation process so that it can remove disease-relevant proteins.

However, resistance to these degraders is still an unsolved issue.

A recent study led by Dr. Cristina Mayor-Ruiz and Dr. Antoni Riera at IRB Barcelona has made significant progress towards understanding and combating resistance to these innovative drugs.

Overcoming Resistance: a persistent challenge in cancer treatment

The development of resistance to cancer treatments is a significant obstacle for the effective management of the disease.

As cancer cells reproduce quickly, they can adapt and become resistant to drugs over time, thereby rendering treatments ineffective.

This issue is particularly problematic with protein degraders, which show great promise but are also susceptible to resistance.

In their study, the researchers tackled this challenge using the cellular model most resistant to protein degraders known to date.

Their primary goal was to find a drug capable of specifically targeting and eliminating these resistant cells.

After an extensive chemical screening and optimisation process, the team identified a drug named RBS-10, which can selectively remove resistant cells and thus emerges as a promising solution to this pressing issue.

NQO1: an actionable vulnerability in resistant cells

To better understand how RBS-10 exerts its effects, the researchers delved into its mechanism of action.

Using chemoproteomics, they pinpointed the enzyme NQO1 as the primary target of RBS-10. Interestingly, the resistant cellular model showed a significant increase in NQO1 expression.

Further analysis through proteomics, metabolomics, and genetic approaches revealed interesting information: RBS-10 acts as a prodrug.

This means that it is activated only after its metabolism by NQO1 in resistant cells.

"We felt like "molecular detectives" in this project, making use of a repertoire of chemical biology approaches to discover that RBS-10 works as a prodrug. Our discoveries not only provide valuable molecular insights into RBS-10´s mechanism of action but also have potential implications for the development of future therapies," commented Dr. Mayor-Ruiz.

Translating findings to clinical applications

As protein degraders continue to progress towards clinical applications, understanding resistance mechanisms is crucial.

“Importantly, drugs in pre-clinical and clinical stages that work like RBS-10 may hold the key to addressing resistance to protein degraders in clinical settings,” concludes Dr. Riera.

First-authored by Barbara Barbosa, Aikaterini Sfyaki and Sergi Rafael, this work is a significant milestone in the ongoing fight against resistance to protein degraders.

With NQO1 identified as a useful player, the scientific community is one step closer to developing innovative strategies to combat resistance and enhance the effectiveness of cancer treatments.

Source: Institute for Research in Biomedicine